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Vilazodone (VLZ) is a selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist
approved for the treatment of major depressive disorder in adults. In preclinical studies, VLZ had
signiﬁcantly lower sexual side effects than SSRIs and reduced serotonin transporter (SERT) levels in
forebrain regions. In the current study, once-daily paroxetine (PAR, 10 mg/kg), VLZ (10 mg/kg),
PAR þ buspirone (BUS, 3 mg/kg; a 5-HT1A partial agonist), or vehicle (VEH) was administered to male rats
for 2 weeks then switched for 7 days (eg, PAR switched to VLZ, PAR þ BUS, or VEH). Sexual behavior (eg,
ejaculation frequency and latency) was evaluated 1-hr postdose on days 1, 7, 14, and 21. After 2 weeks,
treatment with PAR but not VLZ resulted in a signiﬁcant decrease in sexual behavior. In a 30-min test, the
range of ejaculation frequency was 3.08e3.5 with VLZ and 1.00e1.92 with PAR (P < 0.05 vs VEH). After
switching from PAR to VEH, PAR þ BUS, or VEH, sexual behaviors were normalized to control levels. In
contrast, the switch from VLZ to PAR resulted in reduced sexual behaviors. This preclinical study showed
that unlike PAR, an SSRI with no 5-HT1A receptor activity, initial treatment with VLZ did not result in
sexual side effects at therapeutically relevant doses. Results in male rats switched from PAR to VLZ or
PAR þ BUS strongly suggest that activation of 5-HT1A receptors may mitigate the sexual side effects
associated with conventional SSRIs.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Major depressive disorder (MDD) is one of the most common
mental disorders worldwide (Bromet et al., 2011), and antide-
pressants such as selective serotonin reuptake inhibitors (SSRIs) are
among the most frequently prescribed drugs (Lindsley, 2012). The
clinical efﬁcacy can be limited, however, due to adverse sexual side
effects that may affect up to 60% of patients treated with SSRIs
(Kennedy and Rizvi, 2009). These SSRI-induced sexual side effects
can lead to treatment noncompliance and discontinuation (Ashton
et al., 2005), which can lower patient quality of life (Hu et al., 2004)
and increase the risk of relapse and recurrence of MDD (Clayton
and Montejo, 2006). Therefore, understanding the neurobiologyrmacology, Utrecht Institute
iversiteitsweg 99, 3584 CG
r Ltd. This is an open access articleunderlying SSRI-induced sexual dysfunction and identifying treat-
ment options with a lower risk of adverse impact on sexual func-
tion may help to optimize the management of MDD and improve
patient outcomes.
Strategies used to mitigate the adverse sexual side effects of
SSRIs include lowering dosage, switching class of antidepressant
medication (eg, norepinephrine-dopamine reuptake inhibitor), or
adding concomitant medications such as a phosphodiesterase in-
hibitor type 5 (PDE5; eg, sildenaﬁl) or 5-HT1A receptor partial ag-
onists (Rizvi and Kennedy, 2013).
Preclinical studies and clinical evidence support a role for 5-
HT1A receptors in modulating sexual behavior. Buspirone and its
major active metabolite, 6-OH-buspirone, act as partial agonists at
presynaptic 5-HT1A receptors in the raphe nuclei (higher afﬁnity)
and at postsynaptic 5-HT1A receptors throughout the brain (lower
afﬁnity) (Wong et al., 2007). Studies inmale rats have shown that 5-
HT1A receptor agonists (8-OH-DPAT, FG-5893, ﬂesinoxan), as well
as the partial agonist buspirone, have a facilitating effect on sexual
behavior (Bijlsma et al., 2014; Chan et al., 2008). In contrast, the 5-under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations
ANOVA analysis of variance
BUS buspirone
DA dopamine
FDA US Food and Drug Administration
MDD major depressive disorder
MPOA medial preoptic area
PAR paroxetine
PDE5 phosphodiesterase inhibitor type 5
PO orally administered
SEM standard error of the mean
SER sertraline
SERT serotonin transporter
SSRI selective serotonin reuptake inhibitor
VLZ vilazodone
VEH vehicle
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behavior when coadministered with the SSRIs citalopram and
paroxetine (Olivier et al., 2011) andwhen administered to serotonin
transporter (5-HTT) knockout rats (Chan et al., 2011). In a clinical
study of depressed patients, addition of the 5-HT1A receptor partial
agonist buspirone improved sexual function in patients who had
been experiencing sexual dysfunction while taking an SSRI (ie,
paroxetine or citalopram) (Landen et al., 1999).
Vilazodone is an SSRI and 5-HT1A receptor partial agonist
approved by the Food and Drug Administration (FDA) for the
treatment of MDD in adults. In clinical trials, vilazodone was
associated with a low adverse impact on sexual function relative to
the high prevalence of sexual dysfunction that was present in the
patients at baseline (Clayton et al., 2013a). In preclinical studies,
acute treatment with vilazodone showed dose-dependent occu-
pancy of 5-HTT and 5-HT1A receptors in the rat cortex and hippo-
campus, with systemic administration of 10 mg/kg vilazodone
producing ~90e100% occupancy at serotonin transporter (SERT)
and 5-HT1A receptors and resulting in a 2-fold increase in extra-
cellular 5-HT in the rat frontal cortex (Hughes et al., 2005). Results
from another preclinical study showed that treatment with vila-
zodone (acute [1 d], subchronic [7 d], or chronic [14 d]) was not
associated with sexual dysfunction in a rat sexual behavior model
(Oosting et al., 2016). Similar treatments with the SSRIs citalopram
and paroxetine were associated with sexual dysfunction, with
vilazodone causing a marked decrease in 5-HT1A receptor levels in
the cortex and hippocampus and the SSRIs causing increased re-
ceptor levels in similar regions.
The current study was conducted to investigate whether
switching treatments from (chronically administered) paroxetine,
an SSRI known to cause sexual dysfunction in rats, to a treatment
that includes both SSRI and 5-HT1A receptor partial agonism (ie,
vilazodone or paroxetine þ buspirone coadministration) normal-
izes rat sexual behaviors. The doses of drugs that were adminis-
tered to rats in this study (vilazodone, paroxetine, buspirone) were
selected based on SERT and 5-HT receptor occupancy data (Hughes
et al., 2005) and because they fall within the dose ranges for animal
paradigms used to screen for antidepressant and anxiolytic activity
(Adamec et al., 2004; Page et al., 2002).2. Experimental procedures
2.1. Animals
Male (300e400 g) and female (200e300 g) Wistar rats (Charles
River Laboratories, FR) were group housed (4 per cage) with food
and water ad libitum. All animal cages were stored in the same
room maintained at 21 C and 55% humidity. Rats were habituated
for 1 week to reversed light/dark schedule (lights off 7:00; lights on
19:00). All experiments were reviewed and approved by Utrecht
University's animal welfare committee (DEC), in accordance with
the European Communities Council Directive of 24 November 1986.
2.2. Drug administrations
Vilazodone hydrochloride was obtained in powder form from
Forest Laboratories, Inc. (an Allergan afﬁliate). Paroxetine hydro-
chloride and buspirone hydrochloride tablets (Sandoz, France)
were purchased from a local pharmacy in generic form. All drugs
were dissolved or suspended in vehicle (1% methylcellulose and
water) and orally administered (PO) between 9:00 and 15:00 (non-
test days) or 1 h before testing. Doses were 10 mg/kg for vilazodone
and paroxetine; 3 mg/kg buspirone was co-administered with
10 mg/kg paroxetine.
2.3. Sexual behavior test
The sexual behavior test was performed as previously described
(Chan et al., 2010). All assessments were performed in the dark
phase of the light/dark-cycle under dim red light conditions.
2.4. Sexual training and selection of male rats
144 male rats were trained (30 min) once weekly for 4
consecutive weeks with an estrus female that was located in an
observation cage behind a clear Plexiglas front. At 36 h before the
test, the female received a subcutaneous injection of 50 mg
estradiol-benzoate dissolved in sesame oil to induce receptivity.
Males that exhibited 2e3 ejaculations during the ﬁnal three 30-min
training sessions were classiﬁed as normal-performers (Pattij et al.,
2005) and were included in the drug testing studies (n ¼ 84).
2.5. Experimental design and testing
Male normal-performers were divided into 7 treatment groups
(n ¼ 8 per group) that consisted of 2 distinct successive pharma-
cological treatments (exception was vehicle-to-vehicle group). The
experimental design is shown in Fig. 1. Rats received the ﬁrst
treatment for 14 d and were switched to the second treatment for
an additional 7 d.
Male rats were placed in an observation cage (30  40  60 cm)
with an estrous female on Day 1 (acute), Day 8 (subchronic), Day 15
(chronic), and Day 22 (7 d after switch) to score sexual behavior.
Evaluations included the frequencies of mounts (no vaginal pene-
tration) and intromissions (vaginal penetration) in the ﬁrst ejacu-
lation series, latency to the ﬁrst ejaculation (time between the ﬁrst
mount or intromission to ﬁrst ejaculation), and ejaculation fre-
quency for the duration of the 30-min test. Copulatory efﬁciency
was deﬁned as: # intromissions/(# intromissions þ #
mounts)  100%. All measurements and scoring were performed
using Observer® 5.0 (Noldus, Wageningen, The Netherlands).
2.6. Statistical analysis
Data for each sexual behavior test day (acute, subchronic,
Fig. 1. Experimental Design. BUS indicates buspirone; PAR, paroxetine; VEH, vehicle; VLZ, vilazodone. N ¼ 8/group.
Table 1
Sexual behaviors following acute, subchronic, and chronic treatments.
Treatment Acute Subchronic Chronic
Ejaculation frequency, #
VEH 2.8 ± 0.4 3.1 ± 0.2 3.2 ± 0.2
PAR 2.6 ± 0.3 0.8 ± 0.3a,b,c 1.5 ± 0.3a,b,c
PAR þ BUS 2.6 ± 0.3 2.3 ± 0.4 2.0 ± 0.3a,c
VLZ 3.0 ± 0.2 3.6 ± 0.2 3.3 ± 0.2
First series ejaculation latency, sec
VEH 367 ± 136 333 ± 59 269 ± 62
PAR 350 ± 99 1329 ± 531a,b,c 910 ± 188a,c
PAR þ BUS 281 ± 66 549 ± 189 522 ± 138
VLZ 280 ± 63 183 ± 31 245 ± 57
First series copulatory efﬁciency, %
VEH 60 ± 7.7 58 ± 2.9 62 ± 3.9
PAR 49 ± 7.2 21 ± 2.3a,b,c 33 ± 3.2a,b,c
PAR þ BUS 51 ± 6.9 38 ± 8a 38 ± 5.0a,c
VLZ 57 ± 4.9 70 ± 4 62 ± 3.9
All data are shown as the mean ± standard error of the mean for all animals in each
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of variance (ANOVA) to determine the effects of treatment on a
particular test day. Each one-way ANOVA included groups that
received the same pre-switch treatment (paroxetine, vilazodone,
and paroxetine þ buspirone) and the vehicle group. When the
ANOVA indicated a signiﬁcant treatment effect, Bonferroni post hoc
corrections were performed to investigate differences between the
treatments.
Time-by-treatment interactions were analyzed using repeated
measure ANOVAs with Greenhouse-Geisser correction. Time was
based on the 4 test days representing acute (Day 1), subchronic
(Day 8), chronic (Day 15), and post-switch treatment (Day 22);
treatment groups were based on pre-switch assignments (eg, par-
oxetine with a switch to vehicle, vilazodone, or
paroxetine þ buspirone) as well as the vehicle control group. All
signiﬁcance testing was 2-sided at the P  0.05 level. All data are
represented as the mean and standard error of the mean (SEM).pre-switch treatment group: VEH (n ¼ 8); PAR (n ¼ 24); PAR þ BUS (n ¼ 8); VLZ
(n ¼ 16). Lower values indicate greater impairment for ejaculation frequency and
copulatory efﬁciency; higher values indicate greater impairment for ejaculation
latency.
Abbreviations: #, number per 30 min; VEH, vehicle (n ¼ 10); PAR, paroxetine
(10 mg/kg; n ¼ 34); BUS, buspirone (3 mg/kg; n ¼ 12); VLZ, vilazodone (10 mg/kg;
n ¼ 24); sec, seconds.
a P  .05 versus vehicle.
b P  .05 versus paroxetine þ buspirone.3. Results
Representative tracings of individual rat sexual behaviors
(mount, intromission, and ejaculations) during the 30-min sex tests
following subchronic (7 d), chronic (14 d), and 7 d post-switch are
shown in Supplemental Fig. 1.c P  .05 versus vilazodone.3.1. Pre-switch treatments
Ejaculation frequency, ﬁrst series ejaculation latency, and ﬁrst
series copulatory efﬁciency following the acute, subchronic, and
chronic treatments are shown in Table 1. Following the acute
treatments with vehicle, paroxetine, paroxetine þ buspirone, or
vilazodone there were no signiﬁcant differences of the sexual be-
haviors (Table 1, Figs. 2 and 3). However, subchronic and chronic
paroxetine treatments resulted in reduced ejaculation frequency,
increased latency to ﬁrst ejaculation, and reduced copulatory efﬁ-
ciency. The paroxetine þ buspirone treatment impaired ejaculation
frequency (chronic) and copulatory efﬁciency (subchronic and
chronic), but had no effect on latency to ﬁrst ejaculation. Vilazo-
done treatment did not result in any differences in sexual behaviorsfrom vehicle treatment. Bonferroni post hoc corrections for com-
parisons between treatment groups on each test day are described
below and shown in Table 1.3.1.1. Comparisons with paroxetine
Comparisons between treatment groups indicated that
paroxetine-treated rats had worse performance on sexual behavior
parameters than the other groups (Table 1, Figs. 2 and 3). Rats in the
paroxetine group had reduced ejaculation frequency following
subchronic and chronic treatment (both time points, P  0.001 vs
all other groups), increased ejaculation latency following sub-
chronic treatment (P  0.001 vs all other groups) and chronic
Fig. 2. Ejaculatory Behavior. Effects of paroxetine (10 mg/kg), vilazodone (10 mg/kg), and paroxetine þ buspirone (10 and 3 mg/kg, respectively) on (A) ejaculation frequency
during the 30-min sex tests and (B) latency to ﬁrst ejaculation in male Wistar rats (n ¼ 8/drug/dose) conducted after acute (Day 1), subchronic (Day 8), and chronic (Day 15)
treatment and after switching treatments for 1 week (Day 22). **P  0.01, ***P  0.001 versus with VEHeVEH based on a one-way ANOVA for the post-switch assessments. Time-by-
treatment interactions were analyzed using repeated measure ANOVAs with Greenhouse-Geisser correction. Abbreviations: ANOVA, analysis of variance; BUS indicates buspirone;
PAR, paroxetine; VEH, vehicle; VLZ, vilazodone.
Fig. 3. Copulatory Efﬁciency. Effects of (A) paroxetine (10 mg/kg), (B) vilazodone (10 mg/kg), and (C) paroxetine þ buspirone (10 and 3 mg/kg, respectively) on copulatory ef-
ﬁciency in male Wistar rats (n ¼ 8/drug/dose) conducted after acute (Day 1), subchronic (Day 8), and chronic (Day 15) treatment and after switching treatments for 1 week (Day 22).
*P  0.05, **P  0.01 compared with VEHeVEH based on a one-way ANOVA for the post-switch assessments. Time-by-treatment interactions were analyzed using repeated measure
ANOVAs with Greenhouse-Geisser correction. Abbreviations: ANOVA, analysis of variance; BUS indicates buspirone; NS, not signiﬁcant; PAR, paroxetine; VEH, vehicle; VLZ,
vilazodone.
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copulatory efﬁciency after subchronic treatment (P  0.001 vs
vehicle and vilazodone; P  0.05 vs paroxetine þ buspirone) and
chronic treatment (P 0.001 vs vehicle and vilazodone; P  0.01 vs
paroxetine þ buspirone).3.1.2. Comparisons with paroxetine þ buspirone
Paroxetine þ buspirone-treated rats had reduced ejaculation
frequency following chronic (but not subchronic) treatment
(P  0.05 vs vehicle; P  0.01 vs vilazodone; Table 1, Fig. 2A), no
changes in ejaculation latency (Table 1, Fig. 2B), and reduced
copulatory efﬁciency following subchronic treatment (P  0.001 vs
vehicle and vilazodone) and chronic treatment (P  0.05 vs vehicle,
P  0.01 vs vilazodone) (Table 1, Fig. 3B).3.1.3. Comparisons with vilazodone
Unlike the paroxetine- and paroxetine þ buspirone-treated rats,
vilazodone-treated rats did not exhibit impairments in any of the
sexual behaviors relative to the vehicle-treated rats (Table 1, Figs. 2
and 3).
Notably, the signiﬁcant differences between vilazodone and
paroxetine þ buspirone for ejaculation frequency and copulatory
efﬁciency (Table 1) suggested that these treatments did not have
equivalent effects on the sexual behaviors.3.2. Post-switch treatments
3.2.1. From paroxetine to paroxetine þ buspirone or vilazodone
Paroxetine-treated rats that had previously exhibited ejacula-
tory and copulatory sexual dysfunction returned to control (ie,
R.S. Oosting et al. / Neuropharmacology 107 (2016) 271e277 275vehicle-vehicle) levels following 7 d treatment with vehicle,
paroxetine þ buspirone, or vilazodone (Figs. 2 and 3A).
3.2.2. From paroxetine þ buspirone to paroxetine
Rats that were switched from paroxetine þ buspirone to par-
oxetine only treatment exhibited decreased ejaculation frequency,
increased latency to ﬁrst ejaculation, and reduced copulatory efﬁ-
ciency compared with vehicle (all P  0.01; Fig. 2A, B and 3B).
3.2.3. From vilazodone to paroxetine
There were no differences in sexual behaviors of vilazodone-
treated rats that were switched to vehicle compared with
vehicle-vehicle controls (Figs. 2 and 3C). Vilazodone-treated rats
that were switched to paroxetine exhibited decreased ejaculation
frequency, increased latency to ﬁrst ejaculation, and decreased
copulatory efﬁciency compared with vehicle-vehicle controls (all
P  0.05; Figs. 2A, B and 3C).
3.2.4. Time-by-treatment interactions
All time-by-treatment interactions were signiﬁcant (P  0.005)
except for the model that analyzed copulatory efﬁciency in the
group that switched from paroxetine þ buspirone to paroxetine
alone and the vehicle control group (Fig. 3B).
4. Discussion
The current study investigated the role of combined 5-HTT in-
hibition and 5-HT1A receptor partial agonism on male rat sexual
behaviors. In general, the results suggest that SSRI-induced sexual
dysfunction was normalized when treatments included both SSRI
and partial 5-HT1A receptor agonism (ie, vilazodone or
paroxetine þ buspirone).
SSRI treatment can cause sexual dysfunction in all 3 phases of
the human sexual response cycle, which includes desire, arousal,
and orgasm (Serretti and Chiesa, 2009; Waldinger et al., 2001).
Male rats exhibit a similar sexual response cycle that includes the
behaviors of approaching and snifﬁng (precopulatory), repeated
intromissions andmounting (copulatory), and ejaculation (Snoeren
et al., 2014). In the current study, male rat sexual behavior was not
affected by acute treatment with paroxetine alone, as was expected
from previous studies that showed no sexual side effects after acute
SSRI administration in rats (Olivier et al., 2011; Waldinger et al.,
2002) or humans (Waldinger et al., 2001). The most robust inhib-
itory effects were seen after subchronic paroxetine treatment, with
some recovery after longer (chronic) exposure. The reason for this
trend is not clear, but we have occasionally observed a tendency
towards recovery in previous studies with similar treatment para-
digms that also used paroxetine as the reference compound
(Bijlsma et al., 2014; Chan et al., 2008; Olivier et al., 2011).
Based on previous evidence showing that administration of 5-
HT1A receptor agonists and partial agonists enhanced male sexual
behaviors in rodents (Arnone et al., 1995; De Jong et al., 2005;
Snoeren et al., 2014) and improved sexual functioning in
depressed patients taking SSRIs (Landen et al., 1999), it was hy-
pothesized that addition of a 5-HT1A receptor partial agonist to SSRI
treatment would mitigate SSRI-associated sexual side effects. The
pre-switch (subchronic, chronic) and post-switch results of the
current study were consistent with this hypothesis, although the
results with vilazodone are perhaps more persuasive than those
with paroxetine þ buspirone (especially after chronic treatment).
Several mechanisms may be involved in SSRI-induced sexual
dysfunction. First, SSRIs such as paroxetine lead to chronic eleva-
tion of extracellular 5-HT, which increases inhibitory tone on sexual
behaviors (Snoeren et al., 2014) and activates negative feedback
mechanisms that reduce the tone of 5-HT neuronal activity viavarious inhibitory autoreceptors (5-HT1A, 5-HT1B, 5-HT1D, 5-HT5A)
located in the raphe nuclei (Barnes and Sharp, 1999; Chan et al.,
2008; Snoeren et al., 2014). 5-HT1A autoreceptors have been
shown to desensitize following chronic pharmacological elevation
(Le Poul et al., 1995; Li et al., 1997) and gene-mediated (5-HTT
knockout rat) elevation (Chan et al., 2011) of extracellular 5-HT
levels, which may partially dampen the feedback mechanism.
Second, neurochemical adaptations related to postsynaptic 5-HT
heteroreceptors (5-HT1A, 5-HT2A, and 5-HT2C receptors) may also
play a role in sexual function (Clayton et al., 2013a; Olivier et al.,
2011). These heteroreceptors are located on GABAergic and gluta-
matergic cell bodies in brain areas that are involved in sexual be-
haviors (eg, hippocampus, septum, amygdala, hypothalamus, and
entorhinal cortex), but the functions of these inhibitory and excit-
atory systems, respectively, on sexual behavior are not well un-
derstood (Sharp et al., 2007). Finally, sexual behavior may also be
regulated by interactions between the 5-HT system and other
systems that involve dopamine, noradrenaline, or oxytocin (Bijlsma
et al., 2014; Rosen et al., 1999; Silverstone et al., 2012; Snoeren,
2015; Snoeren et al., 2014).
The generally comparable effects of vilazodone and
paroxetine þ buspirone on sexual behavior that were seen in this
study may be due to their activity at both presynaptic 5-HT1A
autoreceptors (Ashby et al., 2013; Wong et al., 2007) and post-
synaptic 5-HT1A heteroreceptors (Hughes et al., 2005; Wong et al.,
2007). 5-HT1A receptor partial agonists stimulate inhibitory autor-
eceptors in the raphe nuclei, which decrease extracellular 5-HT
release globally and thereby reduce inhibitory tone on sexual
behavior. 5-HT1A receptor partial agonists also directly stimulate
postsynaptic 5-HT1A heteroreceptors in brain regions that are
involved in sexual behaviors (Blier and Ward, 2003; Snoeren et al.,
2014); moreover, these heteroreceptors may play a role in negative
feedback loops that inhibit 5-HT transmission (Casanovas et al.,
1999; Hajos et al., 1999; Snoeren et al., 2014).
Although both buspirone and vilazodone are partial 5-HT1A re-
ceptor agonists, buspiorone is also a dopamine D2 receptor
antagonist; additionally, buspirone has an active metabolite, 6-
hydroxybuspirone, that may affect its 5-HT1A receptor occupancy
(Wong et al., 2007). It is important to note, however, that differ-
ences in 5-HT1A occupancy between vilazodone and buspirone
remain unclear since it is a challenge to demonstrate vilazodone's
in vivo 5-HT1A binding afﬁnity due to competition with the
endogenous ligand (5-HT) (van Amsterdam and Seyfried, 2014).
However, in a small clinical study of healthy volunteers, positon-
emission tomography scans showed preferential occupancy for
the presynaptic versus the postsynaptic 5-HT1A receptor with
vilazodone but not with buspirone (Rabiner et al., 2000). Further
research would be needed to better understand the differential
effects of buspiorone and vilazodone on human sexual functioning.
In summary, daily vilazodone treatmentwas not associatedwith
sexual dysfunction in male rats, and switching to daily vilazodone
treatment for 1 week normalized sexual function in rats that had
previously exhibited paroxetine-induced sexual dysfunction. Vila-
zodone treatment may not result in sexual dysfunction in male rats
due to its molecular actions as both an SSRI and 5-HT1A receptor
partial agonist; any effects onmale rat sexual behaviors were found
to be less severe than the coadministration of
paroxetine þ buspirone. In addition, switching to vilazodone
treatment was more effective than the addition of buspirone in
normalizing SSRI-induced sexual side effects, which may have
clinical implications. Combination therapy of SSRIs with 5-HT1A
agonists and partial agonists has been shown to improve SSRI-
related sexual dysfunction (Clayton and Montejo, 2006; Landen
et al., 1999) and is therefore a common strategy to manage treat-
ment in MDD patients experiencing sexual side effects (Rizvi and
R.S. Oosting et al. / Neuropharmacology 107 (2016) 271e277276Kennedy, 2013). Placebo- and active-controlled trials in patients
with MDD (Clayton et al., 2013b, 2015) and placebo-controlled
trials in generalized anxiety disorder (Clayton et al., 2016) have
shown that vilazodone monotherapy is not associated with
treatment-emergent sexual side effects. From a clinical standpoint,
the relative beneﬁts of an adjunctive versus montherapeutic
approach may need to be considered when treating patients who
require serotonergic medications.
Role of funding source
Funding for this study was provided by Forest Laboratories, Inc.,
an Allergan afﬁliate.
Contributors
The study was designed by R. Oosting, J. Chan, and B. Olivier in
consultation with P. Banerjee. Experiments were conducted by J.
Chan and R. Oosting. All authors contributed to the interpretation of
results and drafting of the manuscript. The ﬁnal manuscript was
approved for submission by all authors.
Potential conﬂicts of interest
Other than support for this study, R. Oosting, J. Chan, and B.
Olivier have no potential conﬂicts of interest to disclose. P. Banerjee
is a full-time employe of Forest Research Institute (Jersey City, NJ,
USA), an Allergan afﬁliate.
Acknowledgment
Writing and editorial assistance was provided by Jonathan
Kelley and Adam Ruth, former employees of Prescott Medical
Communications Group (Chicago, IL, USA), with support from For-
est Research Institute, an Allergan afﬁliate.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.neuropharm.2016.03.045.
References
Adamec, R., Bartoszyk, G.D., Burton, P., 2004. Effects of systemic injections of vila-
zodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor
agonist, on anxiety induced by predator stress in rats. Eur. J. Pharmacol. 504,
65e77.
Arnone, M., Baroni, M., Gai, J., Guzzi, U., Desclaux, M., Keane, P., LeFur, G., Soubrie, P.,
1995. Effect of SR 59026A, a new 5-HT1A receptor agonist, on sexual activity in
male rats. Behav. Pharmacol. 276e282.
Ashby Jr., C.R., Kehne, J.H., Bartoszyk, G.D., Renda, M.J., Athanasiou, M., Pierz, K.A.,
Seyfried, C.A., 2013. Electrophysiological evidence for rapid 5-HT(1)A autor-
eceptor inhibition by vilazodone, a 5-HT(1)A receptor partial agonist and 5-HT
reuptake inhibitor. Eur. J. Pharmacol. 714, 359e365.
Ashton, A.K., Jamerson, B.D., L. Weinstein, W., Wagoner, C., 2005. Antidepressant-
related adverse effects impacting treatment compliance: results of a patient
survey. Curr. Ther. Res. Clin. Exp. 66, 96e106.
Barnes, N.M., Sharp, T., 1999. A review of central 5-HT receptors and their function.
Neuropharmacology 38, 1083e1152.
Bijlsma, E.Y., Chan, J.S., Olivier, B., Veening, J.G., Millan, M.J., Waldinger, M.D.,
Oosting, R.S., 2014. Sexual side effects of serotonergic antidepressants: medi-
ated by inhibition of serotonin on central dopamine release? Pharmacol. Bio-
chem. Behav. 121, 88e101.
Blier, P., Ward, N.M., 2003. Is there a role for 5-HT1A agonists in the treatment of
depression? Biol. Psychiatry 53, 193e203.
Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., De Girolamo, G., De
Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., 2011. Cross-national epidemiology
of DSM-IV major depressive episode. BMC Med. 9, 90.
Casanovas, J.M., Hervas, I., Artigas, F., 1999. Postsynaptic 5-HT1A receptors control
5-HT release in the rat medial prefrontal cortex. Neuroreport 10, 1441e1445.
Chan, J.S., Olivier, B., de Jong, T.R., Snoeren, E.M., Kooijman, E., van Hasselt, F.N.,Limpens, J.H., Kas, M.J., Waldinger, M.D., Oosting, R.S., 2008. Translational
research into sexual disorders: pharmacology and genomics. Eur. J. Pharmacol.
585, 426e435.
Chan, J.S., Snoeren, E.M., Cuppen, E., Waldinger, M.D., Olivier, B., Oosting, R.S., 2011.
The serotonin transporter plays an important role in male sexual behavior: a
study in serotonin transporter knockout rats. J. Sex. Med. 8, 97e108.
Chan, J.S., Waldinger, M.D., Olivier, B., Oosting, R.S., 2010. Drug-induced sexual
dysfunction in rats. Curr. Protoc. Neurosci. Chapter 9, Unit 9.34.
Clayton, A.H., Durgam, S., Tang, X., Chen, C., Ruth, A., Gommoll, C., 2016. Charac-
terizing sexual function in patients with generalized anxiety disorder: a pooled
analysis of 3 vilazodone studies. Neuropsychiatr. Dis. Treat. (in press).
Clayton, A.H., Gommoll, C., Chen, D., Nunez, R., Mathews, M., 2015. Sexual
dysfunction during treatment of major depressive disorder with vilazodone,
citalopram, or placebo: results from a phase IV clinical trial. Int. Clin. Psycho-
pharmacol. 30, 216e223.
Clayton, A.H., Kennedy, S.H., Edwards, J.B., Gallipoli, S., Reed, C.R., 2013a. The effect
of vilazodone on sexual function during the treatment of major depressive
disorder. J. Sex. Med. 10, 2465e2476.
Clayton, A.H., Kennedy, S.H., Edwards, J.B., Gallipoli, S., Reed, C.R., 2013b. The effect
of vilazodone on sexual function during the treatment of major depressive
disorder. J. Sex. Med. 10, 2465e2476.
Clayton, A.H., Montejo, A.L., 2006. Major depressive disorder, antidepressants, and
sexual dysfunction. J. Clin. Psychiatry 67 (Suppl. 6), 33e37.
De Jong, T., Pattij, T., Veening, J., Dederen, P., Waldinger, M., Cools, A., Olivier, B.,
2005. Effects of chronic paroxetine pretreatment on (±)-8-hydroxy-2-(di-n-
propyl-amino) tetralin induced c-fos expression following sexual behavior.
Neuroscience 134, 1351e1361.
Hajos, M., Hajos-Korcsok, E., Sharp, T., 1999. Role of the medial prefrontal cortex in
5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br. J.
Pharmacol. 126, 1741e1750.
Hu, X.H., Bull, S.A., Hunkeler, E.M., Ming, E., Lee, J.Y., Fireman, B., Markson, L.E., 2004.
Incidence and duration of side effects and those rated as bothersome with
selective serotonin reuptake inhibitor treatment for depression: patient report
versus physician estimate. J. Clin. Psychiatry 65, 959e965.
Hughes, Z.A., Starr, K.R., Langmead, C.J., Hill, M., Bartoszyk, G.D., Hagan, J.J.,
Middlemiss, D.N., Dawson, L.A., 2005. Neurochemical evaluation of the novel 5-
HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur. J.
Pharmacol. 510, 49e57.
Kennedy, S.H., Rizvi, S., 2009. Sexual dysfunction, depression, and the impact of
antidepressants. J. Clin. Psychopharmacol. 29, 157e164.
Landen, M., Eriksson, E., Agren, H., Fahlen, T., 1999. Effect of buspirone on sexual
dysfunction in depressed patients treated with selective serotonin reuptake
inhibitors. J. Clin. Psychopharmacol. 19, 268e271.
Le Poul, E., Laaris, N., Doucet, E., Laporte, A.-M., Hamon, M., Lanfumey, L., 1995. Early
desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with
ﬂuoxetine or paroxetine. Naunyn Schmiedeb. Arch. Pharmacol. 352, 141e148.
Li, Q., Muma, N., Battaglia, G., Van de Kar, L., 1997. A desensitization of hypothalamic
5-HT1A receptors by repeated injections of paroxetine: reduction in the levels
of G(i) and G(o) proteins and neuroendocrine responses, but not in the density
of 5-HT1A receptors. J. Pharmacol. Exp. Ther. 282, 1581e1590.
Lindsley, C.W., 2012. The top prescription drugs of 2011 in the United States: an-
tipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem.
Neurosci. 3, 630e631.
Olivier, B., Chan, J.S., Snoeren, E.M., Olivier, J.D., Veening, J.G., Vinkers, C.H.,
Waldinger, M.D., Oosting, R.S., 2011. Differences in sexual behaviour in male and
female rodents: role of serotonin. Curr. Top. Behav. Neurosci. 8, 15e36.
Oosting, R.S., Chan, J.S., Olivier, B., Banerjee, P., Choi, Y.K., Tarazi, F., 2016. Differential
effects of vilazodone versus citalopram and paroxetine on sexual dysfunction
and serotonin transporter and receptors in male rats. Psychopharmacology 233,
1025e1034.
Page, M.E., Cryan, J.F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D.R., Lucki, I., 2002.
Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3-indolyl)-butyl)-
butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): a combined
selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor
partial agonist. J. Pharmacol. Exp. Ther. 302, 1220e1227.
Pattij, T., de Jong, T.R., Uitterdijk, A., Waldinger, M.D., Veening, J.G., Cools, A.R., van
der Graaf, P.H., Olivier, B., 2005. Individual differences in male rat ejaculatory
behaviour: searching for models to study ejaculation disorders. Eur. J. Neurosci.
22, 724e734.
Rabiner, E.A., Gunn, R.N., Wilkins, M.R., Sargent, P.A., Mocaer, E., Sedman, E.,
Cowen, P.J., Grasby, P.M., 2000. Drug action at the 5-HT 1A receptor in vivo:
autoreceptor and postsynaptic receptor occupancy examined with PET and
[carbonyl-11 C] WAY-100635. Nucl. Med. Biol. 27, 509e513.
Rizvi, S.J., Kennedy, S.H., 2013. Management strategies for SSRI-induced sexual
dysfunction. J. Psychiatry Neurosci. 38, E27eE28.
Rosen, R.C., Lane, R.M., Menza, M., 1999. Effects of SSRIs on sexual function: a critical
review. J. Clin. Psychopharmacol. 19, 67e85.
Serretti, A., Chiesa, A., 2009. Treatment-emergent sexual dysfunction related to
antidepressants: a meta-analysis. J. Clin. Psychopharmacol. 29, 259e266.
Sharp, T., Boothman, L., Raley, J., Queree, P., 2007. Important messages in the ‘post’:
recent discoveries in 5-HT neurone feedback control. Trends Pharmacol. Sci. 28,
629e636.
Silverstone, P.H., Lalies, M.D., Hudson, A., 2012. Quetiapine and buspirone both
elevate cortical levels of noradrenaline and dopamine in vivo, but do not have
synergistic effects. Front. Psychiatry 3, 82.
R.S. Oosting et al. / Neuropharmacology 107 (2016) 271e277 277Snoeren, E.M., 2015. The role of adrenoceptors in the central nervous system in
male and female rat sexual behavior. Eur. J. Pharmacol. 753, 229e245.
Snoeren, E.M., Veening, J.G., Olivier, B., Oosting, R.S., 2014. Serotonin 1A receptors
and sexual behavior in male rats: a review. Pharmacol. Biochem. Behav. 121,
102e114.
van Amsterdam, C., Seyfried, C.A., 2014. Mechanism of action of the bimodal anti-
depressant vilazodone: evidence for serotonin1A-receptor-mediated auto-
augmentation of extracellular serotonin output. Psychopharmacology 231,
2547e2558.
Waldinger, M.D., van De Plas, A., Pattij, T., van Oorschot, R., Coolen, L.M.,Veening, J.G., Olivier, B., 2002. The selective serotonin re-uptake inhibitors
ﬂuvoxamine and paroxetine differ in sexual inhibitory effects after chronic
treatment. Psychopharmacology 160, 283e289.
Waldinger, M.D., Zwinderman, A.H., Olivier, B., 2001. SSRIs and ejaculation: a
double-blind, randomized, ﬁxed-dose study with paroxetine and citalopram.
J. Clin. Psychopharmacol. 21, 556e560.
Wong, H., Dockens, R.C., Pajor, L., Yeola, S., Grace, J.E., Stark, A.D., Taub, R.A.,
Yocca, F.D., Zaczek, R.C., Li, Y.-W., 2007. 6-Hydroxybuspirone is a major active
metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxy-
tryptamine1A receptor occupancy in rats. Drug Metab. Dispos. 35, 1387e1392.
